Regeneron Sinks 10% After Phase 3 Melanoma Trial Failure

Regeneron Pharmaceuticals (REGN) shares fell 10% in trading on Monday after the company announced that its Phase 3 trial of fianlimab (in combination with Libtayo) in advanced melanoma failed to meet the primary endpoint.

Trial Details

The trial evaluated the efficacy of fianlimab plus Libtayo (cemiplimab) versus placebo plus Libtayo in patients with unresectable or metastatic melanoma. The combination did not show a statistically significant improvement in progression-free survival (PFS) compared to placebo.

Market Reaction

Despite the sharp decline, RBC Capital Markets maintained its positive rating on the stock with a high price target. Analysts noted that Regeneron's pipeline of other drugs, including Eylea and Dupixent, remains strong and that the trial failure does not impact the company's long-term outlook.

Context

The drop comes after a strong year for the stock, which had risen 15% year-to-date before this announcement. Some analysts view the current pullback as a potential buying opportunity for long-term investors.

What This Means for Investors

The Phase 3 trial failure is a setback for Regeneron's oncology program, but it does not threaten the company's fundamentals. Investors should monitor future developments in the company's pipeline, particularly in other areas such as ophthalmology and immunology.